SCAD

Stem Cell & Device Laboratory, Inc. (SCAD) is a biotechnology company based in Kyoto, Japan, specializing in the development of regenerative medicine and drug discovery tools using pluripotent stem cells (iPS and ES cells). Founded in 2014 as a spin-off from Kyoto University, the company has established a proprietary method for the high-efficiency, large-scale production of Schwann cells, which are essential for nerve repair and regeneration. SCAD's primary therapeutic focus is on treating peripheral nerve injuries, carpal tunnel syndrome, and spinal cord injury, with clinical trials expected to commence in 2026. Additionally, the company provides disease-specific iPS cell models and contract assay services to support pharmaceutical research in neuropathy and myopathy. By leveraging its expertise in stem cell differentiation and 3D cell culture, SCAD aims to provide innovative solutions for intractable neurological diseases.